Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDK001 (oral arsenic trioxide) pharmacokinetics in APL
NCT06882031Phase 1Completed
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Arsenol in acute promyelocytic leukemia (APL) (4 arms). Primary endpoint: Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) compared to Intravenous Arsenic Trioxide at 4 weeks. Started Mar 2025; status: completed.
02
Drugs
Arsenol
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT06882031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882031.